{
    "clinical_study": {
        "@rank": "16650", 
        "arm_group": [
            {
                "arm_group_label": "Valsartan 160mg, Rosuvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days."
            }, 
            {
                "arm_group_label": "Rosuvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastatin 20mg is administered daily by mouth once a day for 7 days."
            }, 
            {
                "arm_group_label": "Valsartan 160mg", 
                "arm_group_type": "Experimental", 
                "description": "Valsartan 160mg is administered daily by mouth once a day for 7 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective : To investigate pharmacokinetics after concomitant administration of\n      valsartan and rosuvastatin compared to single administration of valsartan or rosuvastatin in\n      healthy male volunteers\n\n      Secondary objective : To investigate safety profiles after the administration of valsartan\n      or rosuvastatin alone and concomitant administration of valsartan and rosuvastatin in\n      healthy male volunteers"
        }, 
        "brief_title": "Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension, Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male of 20 to 45 years of age at screening\n\n          2. 19 kg/m2 \u2264 BMI\u2264 27 kg/m2 at screening\n\n          3. 90 mmHg \u2264SBP<140 mmHg and 60 mmHg \u2264DBP<90 mmHg at sitting position at screening\n\n          4. At screening\n\n               -  AST and ALT \u2264 1.5 times of upper normal limit\n\n               -  Serum total bilirubin \u2264 1.5 times of upper normal limit\n\n               -  CK \u2264 2 times of upper normal limit\n\n          5. A subject who is able to understand the study, to participate whole periods of the\n             study and to provide written informed consent voluntarily after being fully informed\n             of the study objectives, procedures and study drug\n\n        Exclusion Criteria:\n\n          1. A subject who has medical history of or has clinically significant hepatic, renal,\n             gastrointestinal, respiratory, musculoskeletal, endocrinological, neurologic,\n             hematologic/oncologic, or cardiovascular disease\n\n          2. A subject with severe renal insufficiency (CrCL < 10mL/min by Cockcroft-Gault\n             estimation)\n\n          3. A subject with a history of gastrointestinal disease (e.g., ulcer, Crohn's disease)\n             or surgery (except a simple appendectomy or repair of a hernia) that may influence\n             the absorption of the study drug\n\n          4. A subject with a history of drug allergies to valsartan, rosuvastatin, or other drugs\n             (e.g., aspirin, antibiotics), or a history of clinically significant allergies\n\n          5. A subject with a history of drug abuse or a positive urine drug screen for\n             barbiturate, benzodiazepine, methamphetamine, cannabinoids, cocaine, or opiate\n\n          6. A subject who has taken any prescribed medication or herbal compounds within 14 days\n             before the first drug administration. In addition, a subject who has taken any\n             over-the-counter drug or vitamin supplement within 7 days before the first drug\n             administration. (However, investigators made the final decision on the eligibility\n             for the trial if all other conditions were satisfied)\n\n          7. A subject who has participated in any other clinical trial and received study drug\n             within 60 days before the first drug administration\n\n          8. A subject who has donated a unit of blood or blood components within 60 days or 30\n             days, respectively, or received a transfusion before the first drug administration\n\n          9. A subject who has taken the drug which inhibits or induces drug metabolism such as\n             barbital\n\n         10. A subject with unusual dietary habit which may influence on the administration,\n             distribution, metabolism or excretion of drugs\n\n         11. A subject who consumes caffeine excessively (> 5 units/day)\n\n         12. A subject with consumes alcohol excessively (> 21 units/week, 1 unit = 10 mL of pure\n             alcohol) or with a history of alcoholism\n\n         13. A heavy smoker ( >10 cigarettes/day)\n\n         14. A subject of positive result in serology tests (HBV, HCV, HIV, or syphilis)\n\n         15. A subject who has hereditary muscle disease or family history of hereditary muscle\n             disease, or who has history of muscle disorder induced by drug\n\n         16. The investigator determines whether or not the subject is eligible for the study\n             after, for example, reviewing clinical laboratory results, ECG result, or for other\n             reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918709", 
            "org_study_id": "LG-VRCL001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }, 
            {
                "arm_group_label": [
                    "Valsartan 160mg, Rosuvastatin 20mg", 
                    "Rosuvastatin 20mg", 
                    "Valsartan 160mg"
                ], 
                "description": "Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug", 
                "intervention_name": "Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "V= Valsartan = brand name : Diovan", 
                    "R= Rosuvastatin = brand name : Crestor"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valsartan", 
                "Antihypertensive Agents", 
                "Hypolipidemic Agents", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Clinical Trial Center, Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open Label, Multiple Dose, Cross-over, Phase I Trial to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers", 
        "other_outcome": {
            "description": "Adverse event monitoring\nClinical laboratory test\nVital signs\nElectrocardiography\nPhysical examination", 
            "measure": "Safety", 
            "safety_issue": "No", 
            "time_frame": "-1d and 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 9d, 10d of Period 1, 2, 3 and 42\u00b12d"
        }, 
        "overall_official": {
            "affiliation": "Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center", 
            "last_name": "Jae-Wook Ko, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cmax,ss and AUC\u03c4,ss of valsartan and rosuvastatin", 
            "measure": "PK parameters of valsartan and rosuvastatin", 
            "safety_issue": "No", 
            "time_frame": "0h (pre-dosing on 6d, 20d, 34d) and 0h (pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 48h, and 72h (on 7d, 21d, 35d). Day 1 0h (only in period 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tmax,ss, Cmin,ss, t1/2,\u03b2 of valsartan and rosuvastatin\nCmax,ss and AUC\u03c4,ss of N-desmethyl rosuvastatin", 
            "measure": "PK parameters of valsartan and rosuvastatin", 
            "safety_issue": "No", 
            "time_frame": "0h (pre-dosing on 6d, 20d, 34d) and 0h (pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 48h, and 72h (on 7d, 21d, 35d). Day 1 0h (only in period 1)"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}